Volume 91 Issue 49 | p. 10 | News of The Week
Issue Date: December 9, 2013

Juno Makes A Grand Entrance

Drug Discovery: Biotech lands hefty financial backing to develop cancer immunotherapies
Department: Business
Keywords: pharmaceuticals, biotech, start-ups, immunotherapy, oncology

Juno Therapeutics, a Seattle-based company focused on cancer immunotherapy, has debuted with a whopping $120 million in financing, one of the biggest-ever initial funding rounds for a biotech firm. Backed by Arch Venture Partners and the Alaska Permanent Fund, the company brings together technology developed at previously rival academic institutions to compete in a hot area of drug development.

With technology from Fred Hutchinson Cancer Research Center, Memorial . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society